ClinicalTrials.gg
CompletedNCT00154492Updated Jan 13, 2017

Use of NovoSeven® in Active Variceal Bleeding

A Phase 2 interventional study of activated recombinant human factor VII in Acquired Bleeding Disorder and Cirrhosis, sponsored by Novo Nordisk A/S. Completed at 44 sites in 12 countries. Open to participants aged 18 Years to 79 Years. Per ClinicalTrials.gov, last updated 2017-01-13.

Sponsored by Novo Nordisk A/S · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
265
Allocation
Randomized
Ages
18 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 172 studies in Fibrosis with a site in France — 34 open to participants now, 39 under way, 4 of them phase 3. Fibrosis · France.

Enrollment
38th of 117
265 · median 135
Started
2004
with 3 others
Phase 2
24 of 172
1 open now
Registered
4th of 172
by date

Among the 172 studies in Fibrosis with a site in France, this one is the 38th largest by enrollment of the 117 interventional ones that give a count, is one of 4 that started in 2004, is one of 24 in phase 2, and was the 4th registered.

Fibrosis

1,271 studies on the registry are indexed under Fibrosis; 277 are open to participants now.

Browse Fibrosis studies →

Open to participants now

34 of the 172 studies in Fibrosis with a site in France are open now. Recruiting first, the newest first:

29 more — sign in →

All 34 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 196 Fibrosis studies recruiting now, 111 (57%) set no upper age limit and 53 (27%) stop at 75 or younger; 15 take children under 18; 19 take healthy volunteers.

This study: 18 Years to 79 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 172 studies in Fibrosis with a site in France, or all of them as a file.
02

Study summary

This trial is conducted in Asia and Europe. The trial is planned to investigate the effectiveness and safety of NovoSeven® in patients with advanced cirrhosis and active variceal bleeding.

03

Conditions studied

  • Acquired Bleeding Disorder
  • Cirrhosis

Browse trials for

Keywords

  • Active variceal bleeding in patients with advanced cirrhosis
04

Who can participate

Ages eligible
18 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Variceal bleeding
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
265 participants (actual)
06

What researchers measure

Primary outcomes

  1. Treatment failure

    Time frame: Within 5 days after first trial product administration

Secondary outcomes

  1. Mortality

  2. Rebleeding

  3. Control of acute bleeding

07

Study locations

44 sites
  • Novo Nordisk Investigational Site
    Wien, A 1090, Austria
  • Novo Nordisk Investigational Site
    Olomouc, 77520, Czech Republic
  • Novo Nordisk Investigational Site
    Prague 4, 140 21, Czech Republic
  • Novo Nordisk Investigational Site
    Praha 2, 12821, Czech Republic
  • Novo Nordisk Investigational Site
    Århus, 8000, Denmark
  • Novo Nordisk Investigational Site
    Helsinki, 00029 HUS, Finland
  • Novo Nordisk Investigational Site
    ANGERS cedex 09, 49033, France
  • Novo Nordisk Investigational Site
    Caen, 14033, France
  • Novo Nordisk Investigational Site
    Clichy, 92 188, France
  • Novo Nordisk Investigational Site
    GRENOBLE cedex, 38043, France
  • Novo Nordisk Investigational Site
    Lille, 59037, France
  • Novo Nordisk Investigational Site
    LIMOGES cedex, 87042, France
  • Novo Nordisk Investigational Site
    MARSEILLE cedex 05, 13385, France
  • Novo Nordisk Investigational Site
    NANTES cedex 1, 44093, France
  • Novo Nordisk Investigational Site
    NICE cedex 3, 06202, France
  • Novo Nordisk Investigational Site
    Paris, 75012, France
  • Novo Nordisk Investigational Site
    Paris, 75013, France
  • Novo Nordisk Investigational Site
    TOULOUSE cedex, 31059, France
  • Novo Nordisk Investigational Site
    Villejuif, 94804, France
  • Novo Nordisk Investigational Site
    Berlin, 13353, Germany
  • Novo Nordisk Investigational Site
    Heidelberg, 69120, Germany
  • Novo Nordisk Investigational Site
    Leipzig, 04103, Germany
  • Novo Nordisk Investigational Site
    München, 81377, Germany
  • Novo Nordisk Investigational Site
    Münster, 48145, Germany
  • Novo Nordisk Investigational Site
    Ulm, 89081, Germany
  • Novo Nordisk Investigational Site
    Shatin, 32, Hong Kong
  • Novo Nordisk Investigational Site
    Milano, 20162, Italy
  • Novo Nordisk Investigational Site
    Napoli, 80131, Italy
  • Novo Nordisk Investigational Site
    Palermo, 30146, Italy
  • Novo Nordisk Investigational Site
    Katowice, 40-752, Poland
  • Novo Nordisk Investigational Site
    Krakow, 31-826, Poland
  • Novo Nordisk Investigational Site
    Warszawa, 02-097, Poland
  • Novo Nordisk Investigational Site
    Badalona, 08916, Spain
  • Novo Nordisk Investigational Site
    Barcelona, 08003, Spain
  • Novo Nordisk Investigational Site
    Barcelona, 08025, Spain
  • Novo Nordisk Investigational Site
    Barcelona, 08036, Spain
  • Novo Nordisk Investigational Site
    Córdoba, 14004, Spain
  • Novo Nordisk Investigational Site
    Madrid, 28007, Spain
  • Novo Nordisk Investigational Site
    Madrid, 28034, Spain
  • Novo Nordisk Investigational Site
    Majadahonda, 28222, Spain
  • Novo Nordisk Investigational Site
    Taipei, 112, Taiwan
  • Novo Nordisk Investigational Site
    Leeds, LS9 7TF, United Kingdom
  • Novo Nordisk Investigational Site
    London, WC1 6HX, United Kingdom
  • Novo Nordisk Investigational Site
    Oxford, OX3 9DU, United Kingdom
08

References and documents

Publications

  • Hsia CC, Chin-Yee IH, McAlister VC. Use of recombinant activated factor VII in patients without hemophilia: a meta-analysis of randomized control trials. Ann Surg. 2008 Jul;248(1):61-8. doi: 10.1097/SLA.0b013e318176c4ec. PubMed 18580208 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2004, a primary completion of Aug 2006 and a completion of Aug 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2005
First posted
Sep 12, 2005
Start
Apr 2004
Primary completionActual
Aug 2006
CompletionActual
Aug 2006
Last update
Jan 13, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 13, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00154492
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Sep 12, 2005
Start date
Apr 2004
Primary completion
Aug 2006
Completion
Aug 2006
Last update
Jan 13, 2017

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Recombinant FVIIa

Start the discussion